Prostate Cancer: Extensive Lymph Node Assessment Offers No Survival Benefit

Lymph Node Dissection: Does It Really Matter?

WASHINGTON, May 19, 2026 — A long-term study has found that extended pelvic lymph node dissection after radical prostatectomy does not improve survival rates for prostate cancer patients. The research, presented at a recent medical conference, contradicts hopes that a more thorough lymph node assessment would lead to better outcomes.

The study focused on patients who underwent radical prostatectomy, a surgical procedure to remove the prostate gland. Researchers investigated whether a more extensive dissection of pelvic lymph nodes would improve survival rates.

What Does This Mean for High-Risk Patients?

Extended pelvic lymph node dissection (ePLND) is a procedure that involves removing more lymph nodes from the pelvic area than a standard dissection. The goal is to ensure that all potentially affected nodes are removed, thereby preventing cancer spread. However, the study found no significant difference in survival rates between patients who underwent ePLND and those who did not.

Interestingly, a subgroup analysis suggested a potential benefit of ePLND in patients with high-grade disease. High-grade disease refers to cancer that is more aggressive and likely to spread. While the overall study did not demonstrate a significant survival benefit, the finding in high-risk patients hints at a possible advantage of more extensive lymph node assessment in this specific group.

Can Patients Expect Changes in Treatment Protocols?

The study's results are likely to influence treatment protocols and guidelines for prostate cancer. With no clear survival benefit from ePLND for all patients, doctors may reconsider the necessity of this more extensive procedure. However, for high-risk patients, a more thorough lymph node assessment might become a more standard approach.

Q: What is extended pelvic lymph node dissection (ePLND)? It aims to ensure that all potentially affected nodes are removed.

Frequently Asked Questions

Q: Does ePLND improve survival rates for prostate cancer patients? A: According to the study, ePLND does not offer a significant survival benefit for prostate cancer patients overall. However, it may have a potential benefit for patients with high-grade disease.

Q: Will treatment protocols change following this study? A: The study's findings are expected to influence treatment guidelines, potentially leading to a more tailored approach to lymph node dissection based on individual patient risk factors.